Depot-Depo-Provera

Depot-Provera – drug with antineoplastic, gestagenny action.

Form of release and structure

Depots-Provera release in the form of suspension for injections: white color (on 1 ml in bottles or one-time syringes or on 3,3 and 6,7 ml in bottles, on 1 bottle or the syringe in a cardboard pack).

Is a part of 1 ml of suspension:

• Active agent: acetate of a medroksiprogesteron – 150 mg;
• Auxiliary components: polysorbate 80, polyethyleneglycol 3350, sodium chloride, propylparaben, methylparaben, water for injections.

Indications to use

• Recurrent breast cancer at women in a menopause (hormonedependent forms);
• Metastatic and/or recurrent cancer of a kidney and endometria.

Contraindications

• Pregnancy and period of breastfeeding (lactation);
• Hypersensitivity to drug components.

Route of administration and dosage

At cancer therapy of a mammary gland of Depot-Provera apply intramusculary. An initial daily dose – 500 mg, course duration – 28 days. Upon termination of this period pass to use of maintenance doses – 2 times a week 500 mg. Therapy should be continued before emergence of signs of regression of a disease.

At cancer therapy of kidneys of Depot-Provera enter intramusculary in an initial dose 400-1000 mg a week. If within several weeks or months the state improves and stabilized, appoint a maintenance therapy on 400 mg a month.

Just before use the bottle needs to be shaken up well (the administered drug has to take a form of homogeneous suspension).

Side effects

During therapy development of disturbances from some systems of an organism is possible:

• Reproductive system: a galactorrhoea, dysfunctional uterine bleeding, an amenorrhea, bloody allocations from a genital tract, morbidity of mammary glands, decrease in a libido or an anorgazmiya, a vaginitis, inflows, bleach, hurt in the bottom of a stomach;
• Alimentary system: nausea, unpleasant feelings or abdominal pains, meteorism;
• Musculoskeletal system: to a joint pain and back, spasms of gastrocnemius muscles;
• System of a blood coagulation: thrombophlebitis, thromboembolisms;
• Central nervous system: dizziness, sleeplessness, the increased nervous irritability, drowsiness, a depression, fatigue, a headache;
• Dermatological reactions: acne, rash, itch, alopecia and hirsutism;
• Allergic reactions: anaphylaxis and anaphylactoid reactions, small tortoiseshell;
• Others: hyperthermia, adynamy, crescent-shaped face and change of body weight.

Special instructions

Before use of Depot-Provera it is necessary to conduct careful examination of the patient.

In case of development of symptoms of a thromboembolism before continuation of therapy it is necessary to estimate a ratio of advantage and risk.

At use of Depot-Provera in high doses in cases of development of a symptom complex of Itsenko-Cushing (a liquid delay, a crescent-shaped face, decrease in tolerance to glucose, increase in arterial pressure) it is necessary to reduce whenever possible a dose and to carefully control a condition of the patient. Also use of high doses of drug can lead to increase in body weight and development of a delay of liquid owing to what it is necessary to show care during therapy of patients on whose condition these disturbances can exert adverse impact.

It is necessary to watch a condition of patients in whose anamnesis there are instructions on treatment concerning depressions as at use of Depot-Provera some patients complained of the depression similar to premenstrual carefully.

When carrying out histologic or cytologic researches of an endometria or a neck of uterus of the histologist it is necessary to warn about the carried-out therapy.

The depot-Provera should be applied with care in a puerperal period, it is connected with the increased risk of long and plentiful uterine bleedings.

It is considered that the carried-out therapy can increase risk of development of osteoporosis.

Use of drug should be stopped at sudden partial or full loss of sight, and also in cases of development of doubling in eyes, a pucheglaziya, migraine attacks. If during inspection the papilledema or damage of vessels of cellulose is revealed, it is not necessary to apply Depot-Provera.

At development of jaundice drug should be cancelled.

Use of Depot-Provera can increase values of indicators of function of a liver, change test results to a prothrombin (a factor of II) and factors of coagulability of blood VII, VIII, IX, X (towards increase), and also to influence results of the next laboratory researches:

• Determination of levels of cortisol, progesterone, estrogen in a blood plasma (towards decrease);
• Determination of levels of gonadotrophins (towards decrease);
• Determination of level of testosterone in a blood plasma (towards decrease);
• Determination of level of pregnandiol in urine (towards decrease);
• Test with sugar loading (glucose loading);
• Determination of level of the specific globulin connecting sex hormones (towards decrease);
• Metapyronew test.

Medicinal interaction

Data on interaction of Depot-Provera with other medicines are absent.

At simultaneous use with aminoglutetimidy perhaps considerable decrease in bioavailability of a medroksiprogesteron of acetate.

Terms and storage conditions

To store in protected from light, the place, dry, unavailable to children, at a temperature of 20-25 °C.

Period of validity – 5 years.